BioCryst Pharmaceuticals reported a quarterly loss of $0.03 per share, beating the Zacks Consensus Estimate of a $0.06 loss. The result also improved from break-even EPS a year ago, indicating modestly better-than-expected profitability performance. The update is likely to be stock-specific rather than sector-wide.
BioCryst Pharmaceuticals reported a quarterly loss of $0.03 per share, beating the Zacks Consensus Estimate of a $0.06 loss. The result also improved from break-even EPS a year ago, indicating modestly better-than-expected profitability performance. The update is likely to be stock-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
